Zentalis has been progressing with azenosertib through multiple programs. This includes monotherapy studies such as ZN-c3-001 and DENALI Part 1b, as well as in combination with niraparib in the ...

(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer ...

Zentalis (ZNTL) Pharmaceuticals announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of ...

Explore Zentalis Pharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ZNTL. FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies ...

Zentalis reports updated DENALI trial results for azenosertib in platinum-resistant ovarian cancer, showing 6.3 months median duration of response. Updated median duration of response (mDOR) of 6. ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals ... MAMMOTH is a multi-arm study that evaluated azenosertib monotherapy and in combination with niraparib in patients with ...

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Zentalis Pharmaceuticals has a 1 year low of $1.61 and a 1 year high of $18.07. The firm’s 50 day moving average price is $2.55 and its two-hundred day moving average price is $3.08. Get ...

Zentalis estimates that about half of PROC patients overexpress Cyclin E1 based on its proprietary immunohistochemistry cutoff. As of the January 13, 2025 data cutoff, the safety and tolerability ...